Biotechnology

Lunai Bioworks

Lunai Bioworks released FY2026 Q3 earnings on May 15 (EST), actual revenue USD 20.94 K, actual EPS USD -0.1028

Lunai Bioworks released FY2026 9 Months earnings on May 15 (EST), actual revenue USD 20.94 K, actual EPS USD -0.0543

Lunai Bioworks Reports $2.57M Net Loss in FY26 Q3, Revenue Drops to $20,942

Lunai Bioworks Completes Merger with Neurobridge IP Holdings

Lunai Bioworks Postpones Special Shareholder Meeting

Lunai Bioworks Acquires Clemann Group's Alzheimer's Drug Assets for $20 Million

Lunai Bioworks released FY2026 Semi-Annual Earnings on February 17 (EST), with actual revenue of USD 0 and EPS of USD 0.044

Lunai Bioworks released FY2026 Q2 earnings on February 17 (EST), actual revenue USD 0, actual EPS USD -0.0766

Lunai Bioworks Secures First LOI for DCCT Platform

Lunai Bioworks released FY2026 Q1 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD 0.1251

Lunai Bioworks Releases Landmark Study on Predictive Biomarkers for Duchenne Muscular Dystrophy

Lunai Bioworks released FY2025 Q4 earnings on September 29 (EST), actual revenue USD 0, actual EPS USD -7.1959

Lunai Bioworks released FY2025 Annual Earnings on September 29, 2025, EST: Actual Revenue USD 0, Actual EPS USD -10.8

Lunai Bioworks released FY2025 Q3 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD 0.0115

Lunai Bioworks released FY2025 9 Months Earnings on May 15 Post-Market (EST), actual revenue USD 0, actual EPS USD -3.1999

Lunai Bioworks released FY2024 9 Months Earnings on May 15 Post-Market (EST), actual revenue USD 0, actual EPS USD -7.5106

Lunai Bioworks released FY2024 Q3 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -5.4

Lunai Bioworks released FY2024 Semi-Annual Earnings on February 19 Post-Market (EST), actual revenue USD 0, actual EPS USD -2.1029

Lunai Bioworks released FY2023 Q3 earnings on February 19 (EST), actual revenue USD 0, actual EPS USD -0.7732

Lunai Bioworks released FY2025 Semi-Annual Earnings on February 19 (EST), actual revenue USD 0, actual EPS USD -3.1983

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LNAI

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP | LNAI Stock News

StockTitan

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP | LNAI Stock News

Lunai Bioworks has disclosed its failure to meet Nasdaq's continued listing standards. The Hearings Panel has set deadlines for the company to comply with the $2.5 million stockholders' equity rule by April 27, 2026, and the $1.00 bid price rule by June 1, 2026. The company completed a merger on May 1, 2026, to restore equity compliance and is awaiting the Panel's decision, while the bid-price compliance issue remains unresolved. A previous determination to delist is currently stayed pending the Panel's ruling.

TradingView

Nasdaq

Lunai Bioworks Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Lunai Bioworks has postponed its Special Meeting of Stockholders to May 8, 2026, to allow more time for voting and to help secure a quorum. The meeting will now be held virtually at 9:00 a.m. ET. This delay follows a Broadridge distribution on April 22, which may have affected broker discretionary voting under NYSE Rule 452. The company anticipates that this postponement will enable brokers to vote on routine matters, including a reverse stock split proposal. The record date remains April 10, 2026, and previously submitted proxies will be voted as postponed unless revoked.

Lunai Bioworks postpones special meeting to May 8 to allow broker discretionary voting

.NDX

.DJI

.SPX

U.S. stock futures were mixed following President Trump's announcement of a three-week ceasefire extension between Israel and Lebanon. As of April 23, Nasdaq 100 futures rose 0.39% and S&P 500 futures increased by 0.03%, while Dow Jones futures fell 0.13%. In regular trading, stocks declined, influenced by rising oil prices and U.S.-Iran tensions. The Nasdaq dropped 0.9%, and both the S&P 500 and Dow lost 0.4%. Upcoming earnings reports from Procter & Gamble, Charter Communications, and Schlumberger are anticipated, along with the Michigan consumer sentiment index release.

- U.S. stock futures showed mixed results as investors reacted to a ceasefire extension in the Middle East and rising oil prices exceeding $100 per barrel.  
- President Trump announced a three-week ceasefire extension between Israel and Lebanon, while futures for the Nasdaq 100 and S&P 500 increased slightly, contrasting with a minor decline in Dow futures.  
- In regular trading, stocks decreased overall, influenced by rising oil prices and tensions with Iran, with major indices briefly reaching record highs before falling back.

Tip Ranks

NASDAQ-100

Dow Jones Industrial Average

S&P 500

Procter & Gamble

Charter Comm

NASDAQ Composite Index

SPDR S&P 500

VG S&P 500

Invesco QQQ Trust

iShares Core S&P 500

U.S. Stock Futures Mixed after Trump Confirms Israel-Lebanon Ceasefire Extension

Lanai has launched its AI @ Work Operating System, designed to help enterprises manage AI workflows effectively. The platform identifies all AI activities within an organization, measures their impact, and provides insights for better investment decisions. Key features include edge-based detection of AI usage, capacity measurement at the workflow level, and a queryable AI @ Work graph connected to existing business systems. This system aims to enhance transparency and accountability in AI operations, enabling leaders to understand and optimize AI performance across their organizations.

prnewswire

09:30 ETLanai Launches AI @ Work Operating System to Help Enterprises Close the AI Accountability Gap

Lunai Bioworks pre-market down 13.13%; NuScale Power pre-market up 9.39%; Cheetah Net Supply Chain pre-market up 134.68%; Myseum pre-market up 122.85%; Meiwutek Technology pre-market up 64.03%

Price Alert

NuScale Power

Pre-market hot trades in US stocks: Lunai Bioworks pre-market down 13.13%; NuScale Power pre-market up 9.39%

Lunai Bioworks(LNAI.US)

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP | LNAI Stock News

Lunai Bioworks Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Lunai Bioworks postpones special meeting to May 8 to allow broker discretionary voting

U.S. Stock Futures Mixed after Trump Confirms Israel-Lebanon Ceasefire Extension

09:30 ETLanai Launches AI @ Work Operating System to Help Enterprises Close the AI Accountability Gap

Pre-market hot trades in US stocks: Lunai Bioworks pre-market down 13.13%; NuScale Power pre-market up 9.39%